Health Affairs, doi: 10.1377/hlthaff.28.5.w832
(Published online July 30, 2009)
© 2009 by Project HOPE
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Outterson, K.
* Articles by Kesselheim, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Outterson, K.
* Articles by Kesselheim, A.

Web Exclusives

How Medicare Could Get Better Prices On Prescription Drugs

Kevin Outterson 1* Aaron Kesselheim 2

1 Kevin Outterson is an associate professor in the Boston University School of Law in Massachusetts.
2 Aaron Kesselheim is an instructor in medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, at Brigham and Women's Hospital and Harvard Medical School in Boston.

*Corresponding author.

  Abstract

Congress may reform drug pricing policies under Medicare Part D as part of a larger health reform effort. Currently, the "noninterference" provision prevents the government from negotiating drug prices on behalf of Medicare Part D prescription drug plans. Commonly considered reform proposals borrow ideas from Medicaid, either through returning dual eligibles to Medicaid drug pricing or by imposing mandatory rebates across the Part D population. We examine a menu of other options, including value-based pricing; expansion of generic and therapeutically equivalent substitution; increased formulary diversity; importation; and limited antitrust waivers. These latter options may reduce federal spending without direct government price negotiations. [Health Aff (Millwood) 2009;28(5): w832-41 (published online 30 July 2009;10.1377/hlthaff.28.5.w832)]

Key Words: Business Of Health, Consumer Issues, Health Reform, Managed Care - Medicare, Medicare, Pharmaceuticals, Health Spending


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?